WWW.KONF.X-PDF.RU
- , ,
 


Pages:     | 1 |   ...   | 8 | 9 ||

: , , ...

-- [ 10 ] --

267. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease/ I. Macdougall, R. Robson, S. Opatrna [et al.]// Clin. J. Am. Soc. Nephrol. 2006. Vol. 1. P. 12111215.

268. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia/ D.P. Steensma, J.A. Sloan, S.R. Dakhil [et al.]// J.

Clin. Oncol. 2011. Vol. 29, 1. P. 97105.

269. Pierce, C.N. Inflammatory cytokine inhibition of erythropoiesis in patients implanted with a mechanical circulatory assist device/ C.N. Pierce, D.F. Larson/ Perfusion. 2005. Vol. 20, 2. P. 8390.

270. Plasma cell leukemia with myelofibrosis/ T. Murayama, T. Matsui, Y. Hayashi [et al.]// Ann Hematol. 1994. Vol. 69, 3. P. 151152.

271. Pooled analysis of individual patient-level data from all randomized, doubleblind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia/ H. Ludwig, J. Crawford, A. Osterborg [et al.]// J. of clin. Oncol. 2009. Vol. 27, 17. P. 28382847.

272. Population-based analysis of the frequency of anemia and its management before and during chemotherapy in patients with malignant lymphoma/ P.T. Truong, T. Parhar, J. Hart [et al.]// Am. J. Clin. Oncol. 2010. Vol. 33, 5. P. 465468.

273. Preconditioning with erythropoietin protects against subsequent ischemiareperfusion injury in rat kidney/ C.W. Yang, C. Li, J.Y. Jung [et al.]// FASEB J. 2003. Vol. 17, 12. P. 17541755.

274. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience/ S. Park, S. Grabar, C. Kelaidi [et al.]// Blood. 2008. Vol. 111, 2. P. 574582.

275. Prevalence and incidence of HIF infaction at five Cginese blood centers/ J.Wang, J. Liu, T. Yang [et al.]// Vox Sang. 2012. Vol. 103, Suppl. 1. P. 18.

276. Production and characterization of anti-recombinant human erythropoietin (rhEPO) monoclonal antibody/ J. Yan, S. Wang, J.B. Mi [et al.]// J. Immunoassay Immunochem. 2004. Vol. 25, 1. P. 91101.

277. Prognostic factors and life expentancy in myelodysplastic syndromes classified according to WHO criteria: a basic of clinical decision making/ L.Malcovati, M.P.

Porta, C. Pascito [et al]// J. Clin. Oncol. 2005. Vol. 23. P. 759475603.

278. Prognostic value of hemoglobin concentration in patients with advanced head and neck cancer treated with combined radio-chemotherapy and surgery/ W. Wagner, R. Hermann, J. Hartlapp [et al.]/ Strahlentherapie und Onkologie. 2000. Vol. 76. P. 7380.

279. Progressive inactivation of the expression of an erythroid transcriptional factor in GM- and G-CSF-dependent myeloid cell lines/ S. Crotta, S. Nicolis, A. Ronchi [et al.]// Nucleic Acids Res. 1990. Vol. 18, 23. P. 68636869.

280. Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of 120 g/L with darbepoetin alfa filgrastim or erythrocyte transfusions/ H. Nisson-Echle, G. Birgegrd, J. Samuelsson [et al.]// Eur. J.

Haematol. 2011. Vol. 87, 3. P. 244252.

281. Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies/ D.J. Straus, M.A. Testa, B.J. Sarokhan [et al.]// Cancer. 2006. Vol.

107, 8. P.19091917.

282. Ramchandren, R. Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia/ R. Ramchandren, C.A. Schiffer// Biologics. 2009. 3. P.

205214.

283. Randomized, double-blind, placebo-controlled trial of erythropoietin in nonsmall-cell lung cancer with disease-related anemia/ J.R. Wright, Y.C. Ung, J.A. Julian [et al.]// J. Clin. Oncol. 2007. Vol. 25, 9. P. 10271032.

284. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies/ A. Osterborg, Y.

Brandberg, V. Molostova [et al.]// J. Clin. Oncol. 2002. Vol. 20, 10. P. 2486 2494.

285. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia/ L. Bastit, A. Vandebroek, S. Altintas [et al.]// J. Clin. Oncol. 2008. Vol. 26, 10. P. 16111618.

286. Ratcliffe, P.J. HIF-1 and HIF-2: working alone or together in hypoxia?/ P.J.

Ratcliffe// J. Clin. Invest. 2007. Vol. 117, 4. P. 862865.

287. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials/ J. Bohlius, K. Schmidlin, C. Brillant [et al.]// Lancet. 2009. Vol. 373. P. 15321542.

288. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma/ A. Osterborg, M.A. Boogaerts, R.

Cimino [et al.]// Blood. 1996. Vol. 87, 7. P. 26752682.

289. Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood stem cell transplant when started soon after engraftment/ F. Baron, P.

Frre, G. Fillet, Y. Beguin// Clin. Cancer. Res. 2003. Vol. 9, 15. P. 55665572.

290. Recombinant human erythropoietin : the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients/ O. Durmaz, M Demirkaya, B. Sevinir// Pediatr. Hematol. Oncol. 2011. Vol. 28, 6. P. 461 468.

291. Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy results of a randomized trial/ J.P. Glossmann, A. Engert, G. Wassmer [et al.]// Ann. Hematol. 2003. Vol. 82, 8. P. 469475.

292. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients/ J. Bohlius, J. Wilson, J. Seidenfeld [et al.]// J.

Natl. Cancer Inst. 2006. Vol. 98. 10. P. 708714.

293. Regulation of hepcidin and ferroportin expression by lipopolysaccharide in splenic macrophages/ X.B. Liu, N.B. Nguyen, K.D. Marquess [et al.]// Blood Cells Mol. Dis. 2005. Vol. 35. P. 4756.

294. Regulation of hepcidin transcription by interleukin-1 and interleukin-6/ P. Lee, H. Peng, T. Gelbart [et al.]// Proc. Nat. Acad. Sci. USA. 2005. Vol. 102. P.

19061910.

295. Regulation of iron homeostasis by the hypoxia-inducible factors (HIFs)/ C.

Peyssonnaux, A. Zinkernagel, R. Schuepbach, R. Johnson// J. Clin. Invest. 2007. Vol. 117, 7. P. 19261932.

296. Report of an international working group to standardize response criteria for myelodysplastic syndromes/ B.D. Cheson, J.M. Bennett, H. Kantarjian [et al.]// Blood.

2000. Vol. 96, 12. P. 36713674.

297. Report of the Committee on Hodgkins disease staging classification/ P.P.

Carbone, H.S. Kaplan, K. Musshof [et al.]// Cancer research. 1971. Vol. 31. P.

18601861.

298. Response to erythropoietin in erythroid subclones of the factor-dependent cell line 32D is determined by translocation of the erythropoietin receptor to the cell surface/ A.R. Migliaccio, G. Migliaccio, A. DAndrea [et al.]// Proc. Natl. Acad. Sci.

USA. 1991. Vol. 88, 24. P. 1108611090.

299. Retrospective nationwide survey of Japanese patients with transfusiondependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality/ M. Takatoku, T. Uchiyama, S. Okamoto [et al.]// Eur. J.

Haematol. 2007. Vol. 78. 487494.

300. rHuEPO and improved treatment outcomes: potential modes of action/ K.

Blackwell, P. Gascn, G. Sigounas, L. Jolliffe// Oncologist. 2004. Vol. 9, Suppl. 5.

P. 4147.

301. rHuEpo before high-dose therapy allows autologous peripheral stem-cell transplantation without red blood cell transfusion: a pilot study/ M. Hunault-Berger, A.

Tanguy-Schmidt, P. Rachieru [et al.]// Bone Marrow Transplant. 2005. Vol. 35, 9. P. 903907.

302. Ribatti, D. Erythropoietin and tumor angiogenesis/ D. Ribatti// Stem Cells Dev.

2010. Vol. 19, 1. P. 14.

303. RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 human ovarian carcinoma cells/ G. Paragh, S.M. Kumar, Z. Rakosy [et al.]// Am. J. Pathol. 2009. Vol. 174, 4. P. 15041514.

304. Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy/ P.L. Zinzani, M. Tani, L. Alinari [et al.]// Leuk.

Lymphoma. 2005. Vol. 46, 10. P. 14491454.

305. Roy, C.N. Iron homeostasis: new tales from the cyipt/ C.N. Roy, C.A. Enns// Blood. 2000. Vol. 96, 13. P. 40204027.

306. Safety and efficacy of recombinant human erythropoietin treatment of anemia associated with multiple myeloma in haemodialysed patients/ P. Ruedin, B. Bertschi, W. Chapais [et al.]// Nephrol. Dial. Transplant. 1993. Vol. 8, 4. P. 315318.

307. Salek, S. EHA SWG Quality of Life and Symptoms Patients needs in hematology: whose perspectives?/ S. Salek, T. Ionova, E. Oliva// Haematologica. 20134. Vol. 98, Suppl. 6. P. 828830.

308. Samuelsson, J. Long-standing resolution of anemia in symptomatic low-grade non-Hodgkin's lymphoma patients treated with recombinant human erythropoietin as sole therapy / J. Samuelsson // Med Oncol. 2002. Vol. 19, 1. P. 6972.

309. Santini, V. Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes/ V. Santini// Oncologist. 2011. Vol. 16, Suppl. 3. P. 3542.

310. Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinas inhibitors/ X.

Huang, S. Patel, N. Ahmed [et al.]/ Drug Des Devel Ther. 2009. 2. P. 215219.

311. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia/ A. Hochhaus, S.G. O'Brien, F. Guilhot [et al.]// Leukemia.

2009. Vol. 23, 6. P.10541061.

312. Smith, T.G. The human side of hypoxia-inducible factor/ T.G. Smith, P.A.

Robbins, P.J. Ratcliffe// Br. J. Haematol. 2008. Vol. 141, 3. - P. 325334.

313. Snow, J.W. Translational isoforms of FOG1 regulate GATA1-interacting complexes/ J.W. Snow, S.H. Orkin// J. Biol. Chem. 2009. Vol. 284, 43. P.

2931029319.

314. Steinbrook, R. Medicare and erythropoietin/ R. Steinbrook// N. Engl. J. Med. 2007. Vol. 356, 1. P. 46.

315. Steurer, M. Prevalence and management of anaemia in haematologic cancer patients receiving cyclic nonplatinum chemotherapy: results of a prospective national chart survey/ M. Steurer, H. Wagner, G. Gastel// Wien. Klin. Wochenschr. 2004. Vol. 116, 11-12. P. 367372.

316. Straus, D.J. Epoetin alfa therapy for parameters with hematologic malignancies and mild anemia/ D.J. Straus// Clin. Lymphoma. 2003. Vol. 4, Suppl. 1. S. 13 17.

317. Structure-function correlation in erythropoietin formation and oxygen sensing in the kidney/ M. LeHir, K.U. Eckardt, B. Kaissling [et al.]// Klin. Wochenschr. 1991.

Vol. 69, 13. P. 567575.

318. Study on serum erythropoietin levels in patients with hematologic malignancies/ B. Han, Y.K Shi, J. Zhu [et al.]// Zhonghua Xue Ye Xue Za Zhi. 2006. Vol. 27, 8. P. 543545.

319. Successful autologous peripheral blood stem cell transplantation in a Jehovah's Witness with multiple myeloma: review of literature and recommendations for highdose chemotherapy without support of allogeneic blood products/ S. Schmitt, V.

Mailaender, G. Egerer [et al.]// Int. J. Hematol. 2008. Vol. 87, 3. P. 289297.

320. Survival effect of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: The LNH03-6B study/ R.

Delarue, C. Haioun, B. Coiffier [et al.]// J. Clin. Oncol. 2011. Vol. 29 (suppl.; abstr 9048).

321. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes/ J.M.

Vardiman, J. Thiele, D.A. Arber [et al.]// Blood. 2009. Vol. 114, 5. P. 937 951.

322. The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy/ F. Dammacco, F. Silvestris, G.L. Castoldi [et al.]/ Int. J. Clin. Lab. Res. 1998. Vol. 28, 2. P. 127134.

323. The efficacy of imatinib mesylate for 124 patients with chronic myeloid leukemia in accelerated and blastic phase/ Q. Jiang, S.S. Chen, B. Jiang [et al.]// Zhonghua Xue Ye Xue Za Zhi. 2007. Vol. 28, 11. P. 721726.

324. The erythropoietin receptor in normal and cancer tissues/ W. Jelkmann, J.

Bohlius, M. Hallek, A.J. Sytkowski// Crit. Rev. Oncol. Hematol. 2008. Vol. 67, 1. P. 3961.

325. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia and inflammation/ G. Nicolas, C. Chauvet, L. Viatte [et al.]// J. Clin. Inv. 2002. Vol. 110. P. 10371044.

326. The gene ofor the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p/ J.C. Winkelmann, L.A. Penny, L.L.

Deaven [et al.]// Blood. 1990. Vol. 76, 1. P. 2430.

327. The HIF hydroxylase is a cellular peroxide sensor that modulates HIF transcriptional activity/ N. Masson, R.S. Singleton, R. Sekirnik [et al.]// EMBO Rep. 2012. Vol. 13, 3. P. 251257.

328. The impact of hemoglobin levels on fatigue and quality of life in cancer patients/ B. Holzner, G. Kemmler, R. Greil [et al.]// Ann. Oncol. 2002. Vol. 13. P. 965973.

329. The level of haemoglobin in anaemic cancer patients correlates positively with quality of life/ M. Lind, C. Vernon, D. Cruickshank [et al.]// Br. J. Cancer. 2002. Vol. 86. P. 12431249.

330. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory/ T.R.Mendoza, X.S. Wang, C.S. Cleeland, [et al.]// Cancer. 1999.

Vol. 85, 5. P. 11861196.

331. The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells. From clinic to bench a critical review/ J. Szenajch, G. Wcislo, J.Y. Jeong [et al.]// Biochim. Biophys. Acta. 2010. Vol. 1806. Vol. 1.

P. 8295.

332. The role of recombinant human erythropoietin alpha in the treatment of chronic anemia in multiple myeloma/ F. Dammacco, G. Luccarelli, M. Prete, F. Silvestris/ Rev. Clin. Exp. Hematol. 2002. Suppl 1. P. 3238.

333. The use of erythropoiesis-stimulating agents in patients with non-myeloid hematological malignancies: a systematic review/ N. Shehata, I. Walker, R. Meyer [et al.]// Ann. Hematol. 2008. Vol. 87, 12. P. 961973.

334. Therapeutic effects of imatinib on chronic myeloid leukemia in different phases and the factors affecting the effects/ W.Y. Zou, D.R. Xu, C. Su [et al.]// Nan Fang Yi Ke Da Xue Xue Bao. 2008. Vol. 28, 9. P.16601662.

335. Time-course analysis of hepcidin, serum iron and plasma cytokine levels injected with LPS/ E. Kemna, P. Pickers, E. Nemeth [et al.]// Blood. 2005. Vol.

106, 5. P. 18641866.

336. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia/ S. Picard, K. Titier, G. Etienne [et al.]// Blood. 2007. Vol. 109. P. 34963499.

337. Tumor Hypoxia has independent predictor impact only in patients with nodnegative cervix cancer/ A. Fules, M. Milosevic, D. Hedley [et al.]// J. Clin. Oncol. 2002. Vol. 20. P. 680687.

338. Tumor necrosis factor alpha inhibits erythroid differentiation in human erythropoietin-dependent cells involving p38 MAPK pathway, GATA-1 and FOG-1 downregulation and GATA-2 upregulation/ I. Buck, F. Morceau, S.

Cristofanon [et al.]// Biochem Pharmacol. 2008. Vol. 76, 10. P. 12291239.

339. Tyrosine kinase inhibitors and solid tumours: case report and review of the literature/ F. Roszkiewicz, R. Garidi, I. Vaida [et al.]// Pharmacology. 2009. Vol.

84, 1. P. 3841.

340. Urao, N. Erythropoietin-mobilized endothelial progenitors enhance reendothelialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia/ N. Urao, M. Okigaki, H. Yamada// Circ. Res. 2006. Vol.

98. P. 14051413.

341. Vardiman, J.W. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms/ J.W. Vardiman// Chem. Biol. Interact. 2010. Vol. 184, 1-2. P. 16 20.

342. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia/ C.L. Bennett, S.M. Silver, B. Djulbegovic [et al.]// JAMA. 2008. Vol.

299, 8. P. 914924.

343. Wang, T. The role of cytokines in lymphoma with anemia/ T. Wang, M.F. Tu, J.

Zhu// Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013. Vol. 21, 2. P. 392395.

344. Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, Phase III, randomized, double-blind, placebocontrolled study/ M. Tsuboi, K. Ezaki, K. Tobinai [et al.]// Jpn. J. Clin. Oncol. 2009.

Vol. 39, 3. P. 163168.

345. Weekly epoetin beta maintains haemoglobin levels and improves quality of life in patients with non-myeloid malignancies receiving chemotherapy/ Y. Suzuki, Y.

Tokuda, Y. Fujiwara [et al.]// Jpn. J. Clin. Oncol. 2008. Vol. 38, 3. P. 214 221.



Pages:     | 1 |   ...   | 8 | 9 ||
 

:

14.02.02 : ...

- 14.01.07 ...

URSUS ARCTOS LINNAEUS, 1758 03.02.04 , ... .. 2015 1. ...

, - 06.01.05 ...

03.03.05 , : .. 2015 1 ...

5 ( ) 03.03.02 : , .-. .. ...

- - 03.02.08 ( ) : ...

IN VITRO 03.02.03 : ...

- - 06.01.05. : ...

(Salmo salar L.) - ( ) 03.02.06 ...







 
<<     |    
2016 www.konf.x-pdf.ru - - , ,

, .
, , , , 1-2 .